Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

Recurrent C. diff infection is when you contract a C ... According to the Centers for Disease Control and Prevention (CDC), 1 in 6 people experience a recurring infection within 2 to 8 weeks ...

We are in permanent communication with the Hospital, with the Intra-hospital control committee and ... University hospital the number of infection cases by C-diff increased towards the end of ...

In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections ...

Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile ... treatment for C. diff infection and to prevent ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited ... rate of 78.8% compared with a historical control of 51.8% (p<0.0001). RBX2660 is a broad-spectrum ...

One in six will develop another C. diff infection within eight weeks, according to the federal Centers for Disease Control ...

Purpose The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed.

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections ... recurrent Clostridioides difficile infection, though safety concerns ...

Acurx Pharmaceuticals (ACXP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on December 10. Analyst ...